FIRST AIRED: June 25, 2019

Nice work! Enjoy the show!


You’re busy. We get it.

Stay on top of the news with our Editor’s Picks newsletter.

US Edition
Intl. Edition
Unsubscribe at any time. One click, it’s gone.

Thanks for signing up!



once jilted at the altar by Fizer botox maker eller again is sitting pretty Monday in a huge deal at V. as buying out again for about sixty three billion dollars to one hundred eighty eight dollars twenty four cents per share offer is forty five percent higher than allergens closing price Monday allergen once a Darling for botox dry I drug wrist asus and other beauty treatments has been under pressure analysts expect the company to break itself up it sure is it lost half their value following Fizer decision to walk away from its acquisition deal three years ago Fraser's offer was two and a half times bigger than Abby's current bid Abby makes a blockbuster arthritis drug Q. Miro you'll seeking to diversify its line up because you mera face competition from cheaper versions in Europe Reuters breaking views analyst rob Siryn every did very well for years just because they had this one drug which is fantastic but as the drugs getting older investors for anything okay you know they can see the end coming the shares of come under a lot of pressure over the past year two years %HESITATION and and hello again %HESITATION it kind of a similar thing you know the the all the deals with great for a while and now investors were starting to over the past couple years two years investors saying okay what have you done you've you've overpaid for all these assets to kind of weak %HESITATION flabby companies getting together and the sell off today in %HESITATION have the shares suggests that investors saying it's not gonna solve the problem Abby shares fell fifteen percent Tuesday afternoon Allergan shares shot up twenty seven percent